Navigation Links
ERT Reports Second Quarter 2011 Operating Results on August 1, 2011
Date:7/22/2011

PHILADELPHIA, July 22, 2011 /PRNewswire/ -- ERT (NASDAQ: ERT) announced today that it will release its operating results for the second quarter 2011 Monday, August 1, after the market closes.  After the release, the Company will host a conference call at 5:00 PM ET that day.

For the conference call, interested participants should dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 when calling internationally. There will be a playback available as well. To listen to the playback, please call 1-877-344-7529 when calling within the United States or 1-412-317-0088 when calling internationally.  Conference code for playback is 10002497.

This call is being webcast by MultiVu and can be accessed at ERT's website at www.ert.com. The webcast may also be accessed via the direct link at http://www.videonewswire.com/event.asp?id=81200.   The webcast can be accessed for up to one year on either site.  

ERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.  It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic Patient Reported Outcomes (ePRO) in multiple modalities across all phases of clinical research.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Media Contact:

Keith Schneck, CFO
Tel: 215-972-0420
kschneck@ert.com


'/>"/>
SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Champions Oncology Reports Full Year 2011 Financial Results
2. ReportsnReports - Daptomycin - Comprehensive Patent Search
3. UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits
4. OncoSec Medical Reports Third Quarter 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
7. Soligenix Reports First Quarter 2011 Financial Results and Reviews Accomplishments
8. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
9. SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
10. PharmAthene Reports First Quarter 2011 Financial and Operating Results
11. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)...  Vyriad Inc. announced today the appointment of ... Directors. "We are delighted to welcome Al ... develop our oncolytic viruses as the next generation of ... , MD, PhD, CEO of Vyriad. "Al and his ... passion for making a difference for cancer patients—their philanthropy ...
(Date:12/7/2016)... Texas , Dec. 7, 2016  Genprex, ... of revolutionary immunogene therapy treatments, today announced that ... practice within a leading strategic communications and advisory ... communications program. The program will combine investor relations, ... objective of raising the profile of Genprex and ...
(Date:12/7/2016)... BOULDER, Colo. , Dec. 7, 2016  Muse ... genome engineering technologies, today announced that Dr. Kevin ... member of the Board of Directors. ... , who becomes the company,s Chief Science Officer as ... and Executive Director of the BioDesign Center at the ...
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, 2016 /PRNewswire/ ... immune modulatory medicines, announced today the initiation of a ... candidate, LYC-30937- E nteric C oated, in patients ... that is estimated to affect as many as 7.5 million ... with approximately 1.5 - 3 million cases being diagnosed ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016   Avanade is helping Williams Martini ... in history, exploit biometric data in order to critically ... the competitive edge against their rivals after their impressive, ... Avanade has worked with Williams during the 2016 season ... (heart rate, breathing rate, temperature and peak acceleration) for ...
(Date:12/7/2016)... , Dec. 7, 2016   Veridium , ... the appointment of new CEO James Stickland ... with decades of experience, has served in senior ... where he specialized in expanding a pipeline of ... portfolios. He most recently served as managing director ...
(Date:12/6/2016)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the ... €500.0 million principal amount of its 1.414% senior unsecured notes ... senior unsecured notes due 2026. The closing ... subject to the satisfaction of customary closing conditions.  The notes ... The Company intends to use the net proceeds ...
Breaking Biology News(10 mins):